CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies entered into a definitive securities purchase agreement for a $2.6 million private placement. The deal covers 7,647,061 ordinary shares (or pre-funded warrants in lieu) plus unregistered series A and series B warrants, all priced at $0.34 per share and accompanying warrants (or $0.3399 per pre-funded warrant and accompanying warrants).
The series A and B warrants each have a $0.34 exercise price, become exercisable on the shareholder approval date, and have terms of two and five years, respectively, after effectiveness of a resale registration statement. CollPlant plans to use the net proceeds for general corporate purposes, working capital, research and development, and to continue evaluating strategic business combinations.
H.C. Wainwright & Co. is acting as exclusive placement agent and will receive cash fees, expense reimbursements, and placement agent warrants to purchase up to 458,824 ordinary shares at $0.425 per share. The securities are being issued in a private placement under U.S. Securities Act exemptions, with CollPlant agreeing to file a resale registration statement for the shares and warrant shares.
CollPlant Biotechnologies reported weak first quarter 2026 results and outlined strategic and R&D updates. Revenue fell to $73,000 from $2.055 million a year earlier, mainly because a $2.0 million milestone payment in Q1 2025 did not repeat. GAAP net loss widened to $3.1 million, or $0.23 per share, versus a $1.5 million loss, or $0.13 per share, in Q1 2025. Cash and cash equivalents were $4.3 million as of March 31, 2026, with $3.0 million used in operating activities in the quarter.
The company implemented a cost reduction plan, cutting headcount by about 50%, which helped lower operating expenses to $2.9 million from $3.5 million. CollPlant is advancing a next-generation photocurable dermal filler platform in final preclinical stages and launched its BioFlex rhCollagen-based bioprinting kit. Management also began evaluating strategic alternatives, including potential acquisitions, strategic transactions and other business combinations, with no decisions or timetable yet.
CollPlant Biotechnologies Ltd director Hugh M. Evans filed an initial ownership report showing his equity stake in the company. He directly holds 315,554 Ordinary Shares and 10,000 Restricted Share Units, of which 3,125 are vested and 6,875 vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service.
Evans also holds two option awards to purchase Ordinary Shares: 24,000 options and 23,000 options, each with an exercise price of $6.39 per share and expiration dates on May 2, 2032 and May 26, 2031, respectively. One grant is fully vested, while 22,500 options from the other grant are vested and the remainder vest on May 2, 2026, subject to continued service. Additional Ordinary Shares are held indirectly: shares beneficially owned by his spouse and shares held by an irrevocable trust for his children, for which he disclaims beneficial ownership.
CollPlant Biotechnologies Ltd. is registering for resale up to 3,296,000 ordinary shares issuable upon exercise of private placement warrants (1,600,000 series A; 1,600,000 series B; 96,000 placement agent warrants). This registration is a resale registration by the selling shareholders; the company will not receive proceeds from resale.
The prospectus names the selling shareholders and notes ordinary shares outstanding of 14,415,128 as of March 17, 2026. The company may receive proceeds only if the warrants are exercised for cash (full cash exercise would yield approximately $4.15 million). Trading symbol: CLGN; last reported sale price: $0.37 per share (April 20, 2026).
CollPlant is registering 3,296,000 ordinary shares for resale by selling shareholders, representing shares issuable upon exercise of private placement warrants.
The prospectus states we will not receive proceeds from resale; however, the company may receive up to $4.15 million if the Private Placement Warrants are exercised for cash. Shares outstanding were 14,415,128 ordinary shares as of March 17, 2026.
CollPlant Biotechnologies reported that Allergan Industrie SAS, an AbbVie company, has exercised its right to terminate their February 2021 development agreement for a dermal and soft tissue filler based on CollPlant’s rhCollagen technology, with termination effective June 8, 2026.
In response, CollPlant is implementing a cost-reduction and workforce optimization plan, cutting its workforce by approximately 50%, which it believes will extend its cash runway into Q4 2026. The company is pursuing new strategic partnerships in aesthetic products, advancing three core programs in regenerative dermal and soft tissue fillers, regenerative breast implants, and rhCollagen bioinks for 3D bioprinting.
CollPlant Biotechnologies Ltd. is registering up to 3,296,000 ordinary shares for resale by selling shareholders, representing shares issuable upon exercise of warrants issued in connection with its February 2026 financing. The prospectus states the company will not receive proceeds from these resales; however, it may receive approximately $4.15 million if the warrants are exercised for cash in full.
The filing discloses 14,415,128 ordinary shares outstanding as of March 17, 2026, lists plan of distribution options for selling shareholders, and provides customary registration and risk disclosures.
CollPlant Biotechnologies reported 2025 GAAP revenue of $2.4 million, up from $515,000 in 2024, mainly from a $2 million AbbVie milestone tied to its dermal filler program. GAAP gross profit was $1.5 million versus a gross loss a year earlier.
GAAP operating expenses fell to $13.0 million from $16.1 million following a cost-reduction plan that cut the workforce by about 25%. GAAP net loss narrowed to $11.5 million, or $0.94 per share, from $16.6 million, while non-GAAP net loss was $10.2 million.
Cash and cash equivalents were $5.6 million as of December 31, 2025, with $9.4 million used in operating activities. The company highlighted progress in regenerative breast implant preclinical studies, launch of its BioFlex 3D bioprinting kit, expansion of North American distribution, and new patents in the U.S., South Korea, and Japan.
CollPlant Biotechnologies files its annual Form 20-F as a regenerative and aesthetic medicine company built around plant-derived recombinant human collagen (rhCollagen) for medical aesthetics and 3D bioprinting.
The company reported a total comprehensive loss of $11.5 million in 2025 and an accumulated deficit of $124.8 million, with $5.6 million in cash and cash equivalents as of December 31, 2025. Management and the independent auditor note substantial doubt about CollPlant’s ability to continue as a going concern due to projected negative operating cash flows and limited liquidity.
CollPlant highlights its global development and commercialization agreement with AbbVie for dermal and soft tissue fillers, under which it has received milestone payments of $14 million in 2021, $10 million in 2023, and $2 million in 2025, while stressing there is no assurance of future payments. The report details extensive risk factors, including funding needs, manufacturing scale-up challenges, regulatory uncertainty for its novel plant-based collagen platform, dependence on strategic partners, and restrictions tied to historical R&D grants from the Israel Innovation Authority.